Tremelimumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Hepatocellular Carcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Bladder Cancer · Phase 3 · investigational in the USUrothelial Carcinoma · Phase 3 · investigational in the US

Also approved (3)
CA
  • IMJUDO® (tremelimumab for injection) in combination with durvalumab is indicated for the first- line treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who require systemic therapy (see 14 Clinical Trials). • When using IMJUDO in combination with durvalumab, consult the Product Monograph for durvalumab for further information on this drug.
Product first approved 2023Health Canada
EU
  • Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.
Product first approved 2023EMA
JP
  • Treatment of unresectable advanced or recurrent non- small-cell lung cancer and unresectable hepatocellular carcinoma
Product first approved 2022PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (21)
Bladder Cancer
Hepatocellular Carcinoma
NCT06921785 · AstraZeneca
2025-05-06 – 2030-03-15 · Hepatocellular Carcinoma
What this study did
NCT07027436 · Hamilton Health Sciences Corporation
2025-11-07 – 2028-10-10 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05301842 · AstraZeneca
2022-03-28 – 2027-02-26 · Hepatocellular Carcinoma
What this study did
NCT05883644 · AstraZeneca
2023-06-27 – 2026-12-30 · Advanced Hepatocellular Carcinoma
What this study did
NCT05557838 · AstraZeneca
2023-02-15 – 2026-09-30 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04585490 · Stanford University
2021-08-25 – 2028-04 · Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
What this study did
NCT02542293 · AstraZeneca
2015-11-03 – 2026-12-31 · Non Small Cell Lung Carcinoma NSCLC
What this study did
Urothelial Carcinoma
Other / comorbidity
NCT03288532 · University College, London
2018-07-19 – 2034-12-01 · Renal Cell Carcinoma
What this study did
NCT03043872 · AstraZeneca
2017-03-27 – 2026-12-31 · Small Cell Lung Carcinoma Extensive Disease
What this study did
NCT02551159 · AstraZeneca
2015-10-15 – 2021-05-21 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT00257205 · AstraZeneca
2006-03 – 2010-08 · Melanoma
What this study did
Phase 2/3 (1)
Hepatocellular Carcinoma
NCT06904170 · UNICANCER
2025-11-14 – 2030-09 · Hepatocellular Carcinoma
What this study did
Phase 2 (128)
Bladder Cancer
NCT03150836 · Terence Friedlander, MD
2017-10-01 – 2024-09-01 · Bladder Cancer
What this study did
NCT03472274 · Fundacion CRIS de Investigación para Vencer el Cáncer
2018-10-25 – 2023-04-12 · Bladder Cancer
What this study did
NCT02527434 · AstraZeneca
2015-11-02 – 2023-03-28 · Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
What this study did
NCT03702179 · Spanish Oncology Genito-Urinary Group
2018-11-19 – 2022-08-16 · Invasive Bladder Cancer
What this study did
NCT03430895 · Memorial Sloan Kettering Cancer Center
2018-01-31 – 2021-02-10 · Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Metastatic Bladder Cancer
What this study did
NCT03234153 · Insel Gruppe AG, University Hospital Bern
2018-07-15 – 2020-05-18 · Muscle-invasive Bladder Cancer
What this study did
Hepatocellular Carcinoma
NCT06999707 · Chang Gung Memorial Hospital
2025-05-22 – 2033-05-31 · HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab, Radiotherapy
What this study did
NCT06999694 · Chang Gung Memorial Hospital
2025-05-22 – 2033-05-31 · HCC - Hepatocellular Carcinoma, Durvalumab, Tremelimumab, Proton Radiotherapy
What this study did
NCT07122089 · Center Eugene Marquis
2026-02-25 – 2030-01-02 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT05451043 · AHS Cancer Control Alberta
2023-07-05 – 2029-10-01 · Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer, Cholangiocarcinoma
What this study did
NCT04430452 · Mary Feng, MD
2022-02-04 – 2029-07-31 · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
What this study did
NCT07081633 · AstraZeneca
2025-08-05 – 2028-12-31 · Hepatocellular Carcinoma
What this study did
NCT06880523 · Canadian Cancer Trials Group
2025-10-21 – 2028-12-31 · Hepatocellular Carcinoma
What this study did
NCT04988945 · The University of Hong Kong
2020-12-01 – 2028-12-31 · HCC
What this study did
NCT06045975 · Assistance Publique - Hôpitaux de Paris
2024-03-28 – 2028-09-27 · HCC - Hepatocellular Carcinoma
What this study did
NCT06994299 · Weill Medical College of Cornell University
2025-10-01 – 2028-07-01 · Hepatocellular Carcinoma (HCC)
What this study did
NCT04522544 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2020-12-15 – 2027-12-31 · Hepatocellular Carcinoma Non-resectable, HCC
What this study did
NCT03937830 · National Cancer Institute (NCI)
2021-03-10 – 2027-12-31 · Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
What this study did
NCT06526104 · The University of Texas Health Science Center at San Antonio
2024-12-02 – 2027-12-01 · Hepatocellular Carcinoma, Cirrhosis, Liver
What this study did
NCT07174570 · Emory University
2026-01-02 – 2027-11-13 · Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
What this study did
NCT07511504 · OHSU Knight Cancer Institute
2026-04-02 – 2027-08-01 · Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
What this study did
NCT07175441 · Riboscience, LLC.
2026-04-10 – 2027-08 · Advanced Unresectable Hepatocellular Carcinoma
What this study did
NCT05063565 · Boston Scientific Corporation
2023-11-03 – 2027-06 · Hepatocellular Carcinoma
What this study did
NCT06698250 · Anwaar Saeed
2024-12-18 – 2027-04-30 · Hepatocellular Carcinoma
What this study did
NCT05844046 · Enrico De Toni
2023-04-06 – 2026-12-31 · Hepatocellular Carcinoma
What this study did
NCT02519348 · MedImmune LLC
2015-10-19 – 2026-12-18 · Hepatocellular Carcinoma
What this study did
NCT05440864 · University Health Network, Toronto
2023-10-26 – 2026-11 · Hepatocellular Carcinoma
What this study did
NCT05809869 · The University of Hong Kong
2023-02-15 – 2026-06-30 · Hepatocellular Carcinoma
What this study did
NCT03482102 · Massachusetts General Hospital
2018-05-14 – 2026-04-30 · Hepatocellular Carcinoma, Biliary Tract Cancer
What this study did
NCT06364007 · Sulai Liu
2024-03-03 – 2026-03-31 · Hepatocellular Carcinoma
What this study did
NCT05864755 · Tianjin Medical University Cancer Institute and Hospital
2023-06-20 – 2025-12 · Unrescetable Hepatocellular Carcinoma
What this study did
NCT05027425 · University of Cincinnati
2021-12-07 – 2024-11-07 · Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension
What this study did
NCT03638141 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-10-02 – 2024-08-20 · Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma
What this study did
NCT02821754 · National Cancer Institute (NCI)
2016-07-05 – 2022-12-31 · Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
What this study did
NCT01008358 · Clinica Universidad de Navarra, Universidad de Navarra
2008-12 – 2012-05 · Hepatocellular Carcinoma, Hepatitis C Virus Chronic Infection
What this study did
Non-Small Cell Lung Cancer
NCT07288034 · City of Hope Medical Center
2026-05-01 – 2028-10-08 · Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT04499053 · Georgetown University
2020-12-09 – 2027-12 · Carcinoma, Non-Small Cell Lung
What this study did
NCT02888743 · National Cancer Institute (NCI)
2017-08-14 – 2027-01-02 · Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
NCT03057106 · Canadian Cancer Trials Group
2017-03-28 – 2026-12-30 · Lung Cancer Metastatic
What this study did
NCT05000710 · Sheba Medical Center
2021-12-09 – 2026-12 · Metastatic or Locally Advanced NSCLC
What this study did
NCT03965468 · ETOP IBCSG Partners Foundation
2019-11-19 – 2026-12 · Non-small Cell Lung Cancer, Stage IV, Oligometastasis
What this study did
NCT03975114 · National Cancer Institute, Naples
2018-12-20 – 2024-06-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03237377 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2017-12-12 – 2024-05-23 · Non-Small Cell Lung Cancer
What this study did
NCT03994393 · University of Sydney
2018-10-23 – 2024-01-31 · EGFR Mutant Advanced Non Small Cell Lung Cancer
What this study did
NCT04625699 · Catherine Shu
2022-12 – 2023-12 · Nonsmall Cell Lung Cancer
What this study did
NCT03319316 · European Organisation for Research and Treatment of Cancer - EORTC
2018-11-01 – 2022-11 · Squamous Non-small Cell Lung Cancer, Non-Squamous Non-small Cell Lung Cancer
What this study did
NCT03022500 · Seoul National University Hospital
2017-05-18 – 2019-11-30 · Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC
What this study did
NCT03130764 · Columbia University
2017-03 – 2017-11-30 · Non-small Cell Lung Cancer
What this study did
Phase 1/2 (34)
Bladder Cancer
NCT05120622 · University of British Columbia
2021-09-01 – 2022-05-01 · Bladder Cancer, High-Risk Cancer, Tremelimumab, Durvalumab, Non-muscle Invasive
What this study did
NCT02643303 · Ludwig Institute for Cancer Research
2016-12-28 – 2022-02-23 · Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
What this study did
Hepatocellular Carcinoma
NCT03539822 · Anwaar Saeed
2018-10-22 – 2029-06-30 · Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
What this study did
NCT06911255 · Yoon Jun Kim
2025-04-18 – 2028-06-30 · Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
What this study did
NCT06608940 · Case Comprehensive Cancer Center
2025-11 – 2028-01-01 · Hepato Cellular Carcinoma (HCC)
What this study did
NCT01853618 · National Cancer Institute (NCI)
2013-05-02 – 2017-06-07 · Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Biliary Cancer
What this study did
Non-Small Cell Lung Cancer
NCT03581487 · M.D. Anderson Cancer Center
2019-04-01 – 2025-10-30 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03164772 · Ludwig Institute for Cancer Research
2017-12-20 – 2021-10-29 · Metastatic Non-small Cell Lung Cancer, NSCLC
What this study did
Urothelial Carcinoma
NCT03317158 · Noah Hahn, M.D.
2017-11-21 – 2029-12-31 · Urothelial Carcinoma, Bladder Cancer
What this study did
NCT03549715 · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
2018-12-06 – 2025-09 · Infiltrating Bladder Urothelial Carcinoma
What this study did
NCT03871036 · The Netherlands Cancer Institute
2019-05-01 – 2025-01-15 · Urothelial Carcinoma
What this study did
Other / comorbidity
NCT05932199 · Baylor College of Medicine
2024-07-03 – 2028-05-31 · Mesothelioma
What this study did
NCT02571725 · New Mexico Cancer Research Alliance
2016-02-23 – 2027-07-15 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
What this study did
NCT03837899 · AstraZeneca
2019-03-07 – 2026-12-31 · Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
What this study did
NCT02962063 · Memorial Sloan Kettering Cancer Center
2016-11 – 2026-11 · Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03784066 · Universitaire Ziekenhuizen KU Leuven
2018-08-27 – 2026-03-24 · Oral Cavity Squamous Cell Carcinoma
What this study did
NCT02499328 · AstraZeneca
2015-08-06 – 2025-10-08 · Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT03212469 · Gustave Roussy, Cancer Campus, Grand Paris
2017-06-20 – 2025-02-24 · Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer
What this study did
NCT03249142 · ARCAGY/ GINECO GROUP
2017-10-18 – 2024-12-31 · Ovarian Cancer
What this study did
NCT03283605 · Centre hospitalier de l'Université de Montréal (CHUM)
2018-07-17 – 2024-12-31 · Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma
What this study did
NCT03518606 · UNICANCER
2018-06-20 – 2024-12-19 · Advanced Solid Tumours, Breast Cancer, Head and Neck Cancer, Cervix Cancer, Prostate Cancer
What this study did
NCT03116529 · University of Maryland, Baltimore
2017-06-21 – 2024-06-21 · Soft Tissue Sarcoma
What this study did
NCT04989218 · University of Alabama at Birmingham
2023-01-30 – 2024-05-01 · Cholangiocarcinoma
What this study did
NCT03751761 · Asan Medical Center
2018-06-11 – 2023-08-30 · Metastatic Gastric Cancer
What this study did
NCT03618134 · Jonsson Comprehensive Cancer Center
2018-10-04 – 2023-06-30 · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma, p16 Positive Neoplastic Cells Present, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
What this study did
NCT03202758 · Centre Georges Francois Leclerc
2017-08-29 – 2023-01-09 · Colorectal Cancer Metastatic
What this study did
NCT03206073 · National Cancer Institute (NCI)
2017-12-07 – 2022-06-30 · Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, Colorectal Neoplasms
What this study did
NCT02735239 · Ludwig Institute for Cancer Research
2016-06-24 – 2022-06-16 · Esophageal Cancer
What this study did
NCT03522584 · University of Washington
2018-05-17 – 2022-01-19 · Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT03693612 · GlaxoSmithKline
2018-11-26 – 2021-09-16 · Neoplasms
What this study did
NCT02311361 · National Cancer Institute (NCI)
2015-03-25 – 2020-12-31 · Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
What this study did
NCT02340975 · MedImmune LLC
2015-03-31 – 2019-04-29 · Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT02205333 · MedImmune LLC
2014-08-13 – 2016-04-08 · Advanced Solid Tumors, Aggressive B-cell Lymphomas
What this study did
NCT00075192 · AstraZeneca
2004-03 – 2006-03 · Prostatic Neoplasms
What this study did
Phase 1 (61)
Bladder Cancer
NCT04073160 · Daniel George, MD
2020-06 – 2026-01 · Bladder Cancer
What this study did
NCT00880854 · University of Wisconsin, Madison
2009-06 – 2011-02 · Bladder Cancer
What this study did
Hepatocellular Carcinoma
NCT06710223 · University of California, San Diego
2025-01-03 – 2027-12 · Hepatocellular Carcinoma
What this study did
NCT05701488 · Jiping Wang, MD, PhD
2023-04-21 – 2027-10-01 · Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
What this study did
NCT04605731 · City of Hope Medical Center
2021-08-03 – 2027-02-23 · BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT03509012 · AstraZeneca
2018-05-02 – 2025-01-08 · Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
What this study did
NCT04287894 · The Netherlands Cancer Institute
2018-12-28 – 2024-11-04 · Stage III NSCLC
What this study did
NCT02639026 · Abramson Cancer Center at Penn Medicine
2016-01-26 – 2023-06-27 · Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
What this study did
NCT03275597 · University of Wisconsin, Madison
2018-02-20 – 2020-07-01 · Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
What this study did
NCT02000947 · MedImmune LLC
2013-10-25 – 2019-09-17 · NSCLC, Non-small Cell Lung Cancer, Lung Cancer
What this study did
NCT02040064 · Gustave Roussy, Cancer Campus, Grand Paris
2014-01 – 2016-03 · Non Small Cell Lung Cancer
What this study did
Urothelial Carcinoma
NCT02812420 · M.D. Anderson Cancer Center
2017-03-07 – 2027-12-31 · Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant, Renal Pelvis Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage II Urethral Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis Cancer AJCC v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
What this study did
Other / comorbidity
NCT06564623 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2025-05-27 – 2029-03 · Biliary Tract Cancers
What this study did
NCT06058663 · Mayo Clinic
2024-06-06 – 2028-11-30 · Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
NCT06824363 · University of California, Irvine
2026-05-25 – 2028-07 · Solid Tumor, Adult, Malignant Solid Tumor, Stomach Adenocarcinoma, Esophageal Adenocarcinoma
What this study did
NCT04005690 · OHSU Knight Cancer Institute
2019-08-01 – 2028-02-01 · Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
What this study did
NCT07391670 · AstraZeneca
2026-03-31 – 2027-08-30 · Solid Tumours
What this study did
NCT02537418 · Canadian Cancer Trials Group
2015-10-16 – 2026-12-31 · Solid Malignancies
What this study did
NCT03923270 · H. Lee Moffitt Cancer Center and Research Institute
2019-06-06 – 2026-12 · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
What this study did
NCT04223648 · Yale University
2020-08-15 – 2025-02 · Malignant Melanoma
What this study did
NCT03802747 · University of Colorado, Denver
2019-08 – 2024-12 · Colorectal Cancer
What this study did
NCT03019003 · Massachusetts General Hospital
2017-03-20 – 2024-09-24 · Head and Neck Cancer
What this study did
NCT03132467 · M.D. Anderson Cancer Center
2017-06-13 – 2024-05-20 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
What this study did
NCT03452332 · M.D. Anderson Cancer Center
2018-07-18 – 2023-08-11 · Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Metastatic Cervical Carcinoma, Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Metastatic Vaginal Adenocarcinoma, Metastatic Vaginal Carcinoma, Metastatic Vulvar Carcinoma, Recurrent Cervical Adenocarcinoma, Recurrent Cervical Carcinoma, Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Adenocarcinoma, Vulvar Squamous Cell Carcinoma
What this study did
NCT02754856 · M.D. Anderson Cancer Center
2016-08-29 – 2023-01-30 · Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
NCT03277482 · Dana-Farber Cancer Institute
2018-06-01 – 2022-07-15 · Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer, Metastatic Vaginal Cancer, Metastatic Vulvar Cancer, Metastatic Endometrial Cancer, Recurrent Cervical Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Recurrent Endometrial Cancer
What this study did
NCT02626130 · M.D. Anderson Cancer Center
2016-03-30 – 2022-06-20 · Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer AJCC v7
What this study did
NCT03122496 · Memorial Sloan Kettering Cancer Center
2017-04-25 – 2022-06-03 · Metastatic Anaplastic Thyroid Cancer
What this study did
NCT03963414 · University of Nebraska
2020-09-25 – 2021-12-15 · Small Cell Lung Carcinoma
What this study did
NCT01975831 · Ludwig Institute for Cancer Research
2013-12-19 – 2021-07-02 · Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer, Renal Cell Carcinoma
What this study did
NCT03144778 · M.D. Anderson Cancer Center
2017-07-12 – 2021-03-15 · Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
What this study did
NCT02616185 · Pfizer
2015-12-30 – 2021-02-23 · Prostatic Neoplasms
What this study did
NCT02978482 · AstraZeneca
2016-12-01 – 2020-11-26 · Advanced Malignancy
What this study did
NCT01938612 · AstraZeneca
2013-09-12 – 2020-11-25 · Advanced Solid Tumors
What this study did
NCT02762006 · Moshe Ornstein
2016-12-20 – 2020-11-06 · Renal Cell Carcinoma, Kidney Cancer
What this study did
NCT02141542 · F. Stephen Hodi, MD
2014-05 – 2020-09-23 · Metastatic Melanoma
What this study did
NCT03089645 · MedImmune LLC
2017-03-21 – 2020-06-23 · Advanced Solid Tumors
What this study did
NCT02485990 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016-01-08 – 2020-03-05 · Primary Peritoneal Carcinoma
What this study did
NCT02261220 · MedImmune LLC
2014-10-13 – 2020-01-27 · Advanced Solid Tumors
What this study did
NCT03005002 · City of Hope Medical Center
2017-06-28 – 2019-11-26 · Metastatic Carcinoma in the Liver, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
What this study did
NCT02658214 · AstraZeneca
2016-04-28 – 2019-11-14 · Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Esophagogastric Junction Neoplasms, Carcinoma, Pancreatic Ductal, Esophageal Squamous Cell Carcinoma
What this study did
NCT02586987 · AstraZeneca
2015-12-28 – 2019-09-20 · Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer
What this study did
NCT02705482 · MedImmune LLC
2016-03-30 – 2019-08-07 · Select Advanced Solid Tumors
What this study did
NCT02117219 · MedImmune LLC
2014-05-20 – 2019-04-30 · Myelodysplastic Syndrome
What this study did
NCT02868632 · NYU Langone Health
2016-08-07 – 2019-03-04 · Pancreatic Cancer
What this study did
NCT02549651 · MedImmune LLC
2016-07-13 – 2019-02-04 · Diffuse Large B-Cell Lymphoma
What this study did
NCT02718911 · Eli Lilly and Company
2016-06-16 – 2018-12-14 · Solid Tumor
What this study did
NCT03085849 · Catherine Shu
2017-12-15 – 2018-11-26 · Extensive-stage Small Cell Lung Cancer
What this study did
NCT02301130 · Kyowa Kirin, Inc.
2014-11-26 – 2018-03-05 · Advanced Solid Tumors
What this study did
NCT02716805 · Ludwig Institute for Cancer Research
2016-12-13 – 2018-02-16 · Multiple Myeloma
What this study did
Early phase / not applicable (2)
Hepatocellular Carcinoma
NCT06796114 · Centre Hospitalier Universitaire de Besancon
2025-06-25 – 2030-01-31 · Hepatocellular Carcinoma
What this study did
Other / comorbidity
NCT02563925 · Memorial Sloan Kettering Cancer Center
2015-09-18 – 2021-07-14 · Metastatic Breast Cancer
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2/3 (1)
Phase 2 (3)
Other / comorbidity
NCT04221555 · Asan Medical Center
2020-05-13 – 2025-04-08 · Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03737968 · Yonsei University
2019-01-02 – 2023-10 · Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx, Oropharynx, Larynx
What this study did
NCT02592551 · Baylor College of Medicine
2016-05-11 – 2022-09-01 · Mesothelioma
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Hepatocellular Carcinoma
NCT07166406 · NRG Oncology
2026-02-26 – 2034-03-10 · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
What this study did
Phase 2 (1)
Other / comorbidity
NCT02701400 · Emory University
2016-04-14 – 2020-08-07 · Recurrent Small Cell Lung Carcinoma
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tremelimumab: this drugApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2Partial signal
NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%.
CabozantinibPhase 3Small moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT04471428: Overall Survival (OS) (Up to approximately 24 months): Atezolizumab + Cabozantinib 10.7 months (95% CI 8.8 to 12.3) vs Docetaxel Monotherapy 10.5 months (95% CI 8.6 to 13) missed
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4Weak signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
GotistobartPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Nogapendekin Alfa Inbakicept (Anktiva)Phase 3Protein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05089734: EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant missed
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
BudigalimabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 2Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
Erdafitinib (Balversa)Phase 2Small moleculeFGFR1-4Weak signal
NCT02699606: NSCLC cohort (n=12): objective response rate 0% (no CR or PR); disease control rate 25.0% (95% CI 5.5-57.2%); 3 patients stable disease, 2 with tumor shrinkage >20%. missed
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
VisugromabPhase 2Monoclonal antibodyGDF-15not yet gradedNo reviewed efficacy summary in this indication
BGB-B2033Phase 1/2Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Enfortumab VedotinPhase 1/2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
NilvanstomigPhase 1/2Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
TuvutromstatPhase 1/2Small moleculeMAT2AWeak signalNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
AKY-1189Phase 1RadiopharmaceuticalNectin-4 (PVRL4)not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
LY4052031Phase 1Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 90 furthest-along competitors are listed; 520 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(50 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tremelimumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (11)
November 2026 (4)
Phase 1/2Esophageal Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2026-11 · NCT02962063 · CT.gov ↗
What to watch
Phase 2Germ Cell Tumor, Nonseminomatous Germ Cell Tumor, Seminoma, Germinomatous Germ Cell Tumor, Dysgerminoma, Pineal Germ Cell TumorActive not recruiting
Est. primary completion 2026-11 · NCT03158064 · CT.gov ↗
What to watch
Phase 1Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma …Recruiting
Est. primary completion 2026-11-30 · NCT06058663 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2026-11-30 · NCT07081633 · CT.gov ↗
What to watch
December 2026 (7)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT05000710 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03965468 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT04585490 · CT.gov ↗
What to watch
Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT03606967 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05844046 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT03937830 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06698250 · CT.gov ↗
What to watch
2027 (20)
January 2027 (2)
Phase 1Solid Tumor, Adult, Malignant Solid Tumor, Stomach Adenocarcinoma, Esophageal AdenocarcinomaRecruiting
Est. primary completion 2027-01 · NCT06824363 · CT.gov ↗
What to watch
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT03601455 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02 · NCT04499053 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-02-23 · NCT04605731 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-04 · NCT07175441 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Combined Hepatocellular and CholangiocarcinomaNot yet recruiting
Est. primary completion 2027-05 · NCT06855225 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-05-01 · NCT05451043 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-06 · NCT05063565 · CT.gov ↗
What to watch
Phase 1Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2027-06-01 · NCT04005690 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaRecruiting
Est. primary completion 2027-06-25 · NCT06796114 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-07-31 · NCT04522544 · CT.gov ↗
What to watch
August 2027 (3)
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-08-01 · NCT07511504 · CT.gov ↗
What to watch
Phase 2ImmunotherapyActive not recruiting
Est. primary completion 2027-08-10 · NCT04169841 · CT.gov ↗
What to watch
Phase 1Solid TumoursRecruiting
Est. primary completion 2027-08-30 · NCT07391670 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-09-27 · NCT06045975 · CT.gov ↗
What to watch
October 2027 (3)
Phase 1Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-10-01 · NCT05701488 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-10-01 · NCT06526104 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-10-12 · NCT07027436 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-12 · NCT06710223 · CT.gov ↗
What to watch
Phase 1Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT02812420 · CT.gov ↗
What to watch
2028 (9)
January 2028 (2)
Phase 2Malignant Solid NeoplasmsRecruiting
Est. primary completion 2028-01 · NCT02029001 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-01-31 · NCT06880523 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-03-31 · NCT06911255 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1/2MesotheliomaRecruiting
Est. primary completion 2028-05-31 · NCT05932199 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT03539822 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-07-31 · NCT04430452 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-08 · NCT07288034 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1/2Bladder CancerActive not recruiting
Est. primary completion 2028-12-31 · NCT03317158 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2028-12-31 · NCT04988945 · CT.gov ↗
What to watch
2029 (3)
March 2029 (1)
Phase 1Biliary Tract CancersRecruiting
Est. primary completion 2029-03 · NCT06564623 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2HCC, Tace, ImmunotherapyNot yet recruiting
Est. primary completion 2029-08-14 · NCT07168668 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2/3Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-09-14 · NCT06904170 · CT.gov ↗
What to watch
2030 (6)
January 2030 (1)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-01-02 · NCT07122089 · CT.gov ↗
What to watch
March 2030 (1)
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-03-15 · NCT06921785 · CT.gov ↗
What to watch
April 2030 (2)
Phase 2Hepato Cellular CarcinomaRecruiting
Est. primary completion 2030-04-01 · NCT07489976 · CT.gov ↗
What to watch
Phase 2CancerRecruiting
Est. primary completion 2030-04-30 · NCT03847649 · CT.gov ↗
What to watch
May 2030 (2)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-05-31 · NCT06999707 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-05-31 · NCT06999694 · CT.gov ↗
What to watch
2032 (1)
July 2032 (1)
Phase 2Colorectal Cancer, Endometrial CancerActive not recruiting
Est. primary completion 2032-07-01 · NCT06680739 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 May 2026Topline resultVOLGA Phase 3 (NCT04960709): perioperative durvalumab plus tremelimumab with neoadjuvant enfortumab vedotin met event-free survival at the interim analysis
Q2 2026Topline resultPhase III NILE: durvalumab plus tremelimumab with chemotherapy missed the overall survival dual primary endpoint